Claims for Patent: 5,811,252

Summary for Patent: 5,811,252

Title:	Modified proenzymes as substrates for proteolytic enzymes
Abstract:	Detection or determination of a protease in a sample by incubating the sample with a substrate of the protease and observing proteolytic cleavage of said substrate. The substrate is a modified proenzyme containing a recognition site, e.g., an activation site, cleavable by said protease. Proteolytic cleavage of the modified proenzyme is detected by observing the resulting activity using a suitable substrate of the activated proenzyme. The protease may be e.g. an aspartic protease or a metalloprotease, and the modified proenzyme e.g. pro-urokinase having a mutant activation site which is cleavable by the protease to be determined.
Inventor(s):	Verheijen; Johan Hendrikus (Rodenrijs, NL)
Assignee:	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL)
Application Number:	08/499,048
Patent Claims:	1. A method of determining a protease, or its precursor after activation, in a sample, comprising incubating the sample with a substrate of said protease, determining proteolytic cleavage of said substrate, and correlating data obtained therefrom in order to determine the protease, wherein said substrate is a modified proenzyme containing a recognition site which is cleavable by said protease. 2. The method as claimed in claim 1 wherein proteolytic cleavage of said modified proenzyme activates the proenzyme and is determined by observing or measuring the resulting activity using a suitable substrate of the activated proenzyme. 3. The method as claimed in claim 1 wherein proteolytic cleavage of said modified proenzyme converts it into a substrate for a secondary enzyme capable of activating the proenzyme, and said proteolytic cleavage of the modified proenzyme is determined by incubating with said secondary enzyme and observing or measuring the resulting activity using a suitable substrate of the activated proenzyme. 4. The method as claimed in claim 1 wherein said sample is selected from the group consisting of a biological fluid, a fraction of a biological fluid, a biological tissue, an extract of a biological tissue, and a fraction of an extract of a biological tissue. 5. The method as claimed in claim 1 wherein said protease is selected from the group consisting of serine proteases, cysteine proteases, aspartic proteases and metalloproteases. 6. The method as claimed in claim 1 wherein said protease is an aspartic protease or a metalloprotease. 7. The method as claimed in claim 1 wherein said protease is a matrix metalloprotease. 8. The method as claimed in claim 7 wherein said matrix metalloprotease is a collagenase, gelatinase or stromelysin. 9. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a proenzyme by replacing its activation site by an activation site which is cleavable by the protease to be determined. 10. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a serine esterase. 11. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a pro-phospholipase. 12. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a serine protease. 13. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a clotting enzyme selected from the group consisting of factor V, factor VII, factor IX, factor X, factor XII and prothrombin. 14. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from a proenzyme selected from the group consisting of trypsinogen, chymotrypsinogen, plasminogen, pro-urokinase, pro-elastase, prosubtilisin and kallikrein. 15. The method as claimed in claim 1 wherein said modified pro-enzyme is derived from pro-urokinase. 16. The method as claimed in claim 15 wherein the pro-urokinase modification is in the region Gly.sup.149 to Glu.sup.168. 17. The method as claimed in claim 15 wherein the pro-urokinase modification is in the sequence Pro.sup.155 -Arg-Phe-Lys-Ile-Ile-Gly-Gly.sup.162. 18. The method as claimed in claim 15 wherein the sequence Pro.sup.155 -Arg-Phe-Lys-Ile-Ile-Gly-Gly.sup.162 is replaced by the sequence Xxx.sup.155 -Pro-Leu-Gly-Ile-Ile-Gly-Yyy.sup.162, wherein Xxx and Yyy can be any aminoacid, to transform the pro-urokinase into a substrate for collagenase and other matrix metalloproteases. 19. The method as claimed in claim 15 wherein the sequence Pro.sup.155 -Arg-Phe-Lys-Ile-Ile-Gly-Gly.sup.162 is replaced by the sequence Arg.sup.155 -Pro-Leu-Gly-Ile-Ile-Gly-Gly.sup.162 to transform pro-urokinase into a substrate for collagenase and other matrix metalloproteases. 20. The method as claimed in claim 15 wherein activation of said modified pro-urokinase is determined using a peptide substrate of urokinase which releases a coloured or fluorescent group upon hydrolysis by urokinase. 21. The method as claimed in claim 15 wherein said peptide substrate is a compound Xxx-Yyy-Arg-pNA, wherein Xxx and Yyy can be any aminoacid and pNA represents a para-nitroaniline moiety. 22. The method as claimed in claim 15 wherein activation of said modified pro-urokinase is determined using plasminogen as urokinase substrate and using a plasmin-specific peptide substrate releasing a coloured or fluorescent group upon hydrolysis by plasmin to determine activation of said plasminogen. 23. The method as claimed in claim 22 wherein said plasmin-specific peptide substrate is selected from the group consisting of H-D-Val-Leu-Lys-pNA, N-isovaleryl-Leu-Lys-pNA, N-isovaleryl-Phe-Lys-pNA, N-acetyl-D-Val-Phe-Lys-pNA, N-acetyl-D-Val-Leu-Lys-pNA, .epsilon.-aminocaproyl-D-Val-Leu-Lys-pNA, N-O-sulphobenzoyl-Val-Leu-Lys-pNA and N-carbobenzoxy-Val-Leu-Lys-pNA. 24. A modified proenzyme derived from a proenzyme by providing it with a recognition site which is cleavable by a protease different from the one which activates the unmodified proenzyme. 25. The modified proenzyme as claimed in claim 24 wherein said recognition site is an activation site cleavable by a protease different from the one which activates the unmodified proenzyme, said activation site replacing the activation site of the proenzyme. 26. The modified proenzyme as claimed in claim 24 which is derived from pro-urokinase. 27. The modified proenzyme as claimed in claim 26 wherein the sequence Pro.sup.155 -Arg-Phe-Lys-Ile-Ile-Gly-Gly.sup.162 is replaced by the sequence Xxx.sup.155 -Pro-Leu-Gly-Ile-Ile-Gly-Yyy.sup.162, wherein Xxx and Yyy can be any aminoacid, to transform the pro-urokinase into a substrate for collagenase and other matrix metalloproteases. 28. The modified proenzyme as claimed in claim 26 wherein the sequence Pro.sup.155 -Arg-Phe-Lys-Ile-Ile-Gly-Gly.sup.162 is replaced by the sequence Arg.sup.155 -Pro-Leu-Gly-Ile-Ile-Gly-Gly.sup.162 to transform the pro-urokinase into a substrate for collagenase and other matrix metalloproteases. 29. A kit for determining a protease, or its precursor after activation, in a sample, comprising a modified proenzyme as defined in claim 24, together with at least one member from the group consisting of substrates for activated proenzyme, secondary enzymes, buffer solutions, standard preparations, specific antibodies, microtiter plates, and instructions for use. 30. A device for determining a protease, or its precursor after activation, in a sample, comprising a modified proenzyme as defined in claim 24.

Details for Patent 5,811,252

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2014-07-07
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-07-07